Investment Portfolio
Portfolio Overview
Chord Capital has traditionally sought to create and develop businesses by investing in strong and innovative intellectual property. It has done this across a wide range of industries, including engineering, materials, medical devices, physical & life sciences, telecommunications, energy and electronics. As portfolio companies have developed, we have utilised our skills in helping to build out the companies towards commercialisation and assisting in the channel partnering process. This progress – from development to commercialisation – is key to generating value and building successful companies.
Atraverda
www.atraverda.com
Atraverda is an advanced materials company that exploits a conductive ceramic known worldwide through its trademark, Ebonex®, a platform technology with a range of commercial CleanTech applications in the power storage, water treatment and construction markets. Atraverda’s current focus is in the multi-billion dollar power storage market, where its technology is utilised in the production of batteries that are smaller, lighter and more reliable. Atraverda most recently completed a funding round of £10 million.
ImmunoBiology
www.immbio.com
ImmBio is a vaccine company developing the next generation of anti-infective vaccines. The portfolio addresses areas of high unmet need, where the risk and consequence of infection are severe. ImmBio has an established product and process patent estate around Heat shock protein Complexes, and has licensed in complementary technology for specific applications. Vaccines are being developed to address influenza, tuberculosis, hepatitis and meningitis. ImmBio most recently completed the second phase of a £5.5 million funding round.
Metalysis
www.metalysis.com
Metalysis is an innovative speciality metals business. Metalysis holds the exclusive worldwide exploitation rights to the FFC Cambridge process – this enables the efficient and environmentally friendly reduction of metals from the metal oxide. Initial focus is on the production of Tantalum and Titanium, though the process can be applied to a wide range of metals, alloys and carbides. Following the successful completion of a £5m funding round, the company is concentrating on the scale-up of production capacity.
FreeHand Surgical
www.freehandsurgeon.com
FreeHand Surgical manufactures and distributes a laparoscopic camera-holding robot called FreeHand. The product entered the market in April 2009 and has achieved wide critical acclaim in the medical industry – against a background of increased demand in the application of robotics in surgery. FreeHand achieved 510k FDA approval in the U.S. in May 2009. FreeHand Surgical raised new funding of £3.25m in May 2010 in order to acquire Prosurgics, the former developer of the technology. The aim of the company is to exploit the laparoscopic (“keyhole”) surgery market in the UK and USA which accounts for 2.5 million procedures each year globally. The technology comprises a robot arm that moves the surgical camera and which saves hospitals time and money. FreeHand Surgical’s “disposables” business model ensures an ongoing revenue stream after the robot arm is in place in operating theatres.
Sensortec
www.sensortec.uk.com
Sensortec has developed a robust and adaptable electrochemical biosensor technology platform based on immunoassay techniques. Sensortec’s initial focus is in environmental monitoring and food quality assurance, where precision of results can be greatly improved, while reducing sample preparation time.
CIP Technologies
www.ciphotonics.com
Through its chairmanship of CIP, Chord Capital has an equity stake in the company. CIP is a manufacturer of photonic components as well as a world-leading design house and prototyper of innovative optoelectronic solutions for a range of OEM customers. The company is embarking upon a radical new product platform aimed at addressing the huge, but largely unmet demand for broadband internet connectivity. This multi-channel array transceiver is effectively an optical PCB.
|
